Wex may modify cancer pain trial

A data monitoring committee analyzing Wex Pharmaceuticals’ (TSX:WXI) Phase 3 clinical trial of  Tetrodotoxin (TTX) in patients with cancer-related pain has  found no safety concerns to stop or modify the trial based on an interim analysis of 60 patients. However, the committee informed Wex that the trial was “unlikely to demonstrate a clinically meaningful treatment-effect [...]

Pharmagesic to bid for Wex shares not already owned

WEX Pharmaceuticals (TSX:WXI) has been advised that Pharmagesic (Holdings) plans to make an unsolicited bid to acquire all of Wex’s outstanding restricted voting shares not currently held by Pharmagesic at a price of 13 cents a share. Wex stock last traded at 10.5 cents last Wednesday. Pharmagesic is a unit of CK Life Sciences International [...]

Wex raises $34.5-million in rights offering

Wex Pharmaceuticals’ (TSX:WXI) rights offering has been fully subscribed, raising $34.5 million through the issuance of 265,483,177 restricted voting shares at a price of 13 cents a share. The company intends to use the proceeds to continue its research and development of tetrodotoxin and for general administrative costs and working capital. Controlling shareholder Pharmagesic (Holdings), [...]

Wex plans $34.5-million rights offering

Wex Pharmaceuticals (TSX:WXI) has filed for a rights offering to raise about $34.5-million, with proceeds earmarked to fund research and development, and for working capital. Under the plan, holders of restricted voting shares of Wex on Dec. 23 will receive rights to purchase 1.5 new shares at a subscription price of 13 cents.  The rights [...]